AFT Pharmaceuticals logo

AFT - AFT Pharmaceuticals News Story

NZD4.8 -0.0  -0.2%

Last Trade - 07/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £261.5m
Enterprise Value £281.4m
Revenue £56.0m
Position in Universe 435th / 1907

BRIEF-Hyloris Pharmaceuticals Says AFT Signed Exclusive License And Supply Agreements For Commercialisation Of Maxigesic IV

Thu 8th April, 2021 6:11am
April 8 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * AFT HAS SIGNED EXCLUSIVE LICENSE AND SUPPLY AGREEMENTS
WITH
MERCAPHARM SP.Z.O.O (“MERCAPHARM”) AND VIANEX SA (“VIANEX”) FOR
THE COMMERCIALISATION OF MAXIGESIC IV IN POLAND AND GREECE
RESPECTIVELY
    * ANNOUNCES FURTHER EXTENSION OF EUROPEAN FOOTPRINT OF
MAXIGESIC®
IV
    * NEW AGREEMENTS IN POLAND AND GREECE, WHICH COVER
TERRITORIES
WITH A TOTAL POPULATION OF >48.5 MILLION PEOPLE
    * AFT EXPECTS TO RECEIVE REGULATORY APPROVAL IN POLAND AND
GREECE
IN MID-2022, WITH SALES EXPECTED TO BEGIN SHORTLY THEREAFTER

Source text: https://bit.ly/3wLb1Kn
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.